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Abstract
Background Survival from paediatric high-risk neuroblastoma (HR-NBL) has increased, but cis-retinoic acid (cis-RA),
the cornerstone of HR-NBL therapy, can cause osteoporosis and premature physeal closure and is a potential threat to
skeletal structure in HR-NBL survivors. Sarcopenia is associated with increased morbidity in survivors of paediatric ma-
lignancies. Low muscle mass may be associated with poor prognosis in HR-NBL patients but has not been studied in
these survivors. The study objective was to assess bone density, body composition and muscle strength in HR-NBL sur-
vivors compared with controls.
Methods This prospective cross-sectional study assessed areal bone mineral density (aBMD) of the whole body, lum-
bar spine, total hip, femoral neck, distal 1/3 and ultradistal radius and body composition (muscle and fat mass) using
dual-energy X-ray absorptiometry (DXA) and lower leg muscle strength using a dynamometer. Measures expressed as
sex-specific standard deviation scores (Z-scores) included aBMD (adjusted for height Z-score), bone mineral apparent
density (BMAD), leg lean mass (adjusted for leg length), whole-body fat mass index (FMI) and ankle dorsiflexion peak
torque adjusted for leg length (strength-Z). Muscle-specific force was assessed as strength relative to leg lean mass.
Outcomes were compared between HR-NBL survivors and controls using Student’s t-test or Mann–Whitney U test.
Linear regression models examined correlations between DXA and dynamometer outcomes.
Results We enrolled 20 survivors of HR-NBL treated with cis-RA [13 male; mean age: 12.4 ± 1.6 years; median
(range) age at therapy initiation: 2.6 (0.3–9.1) years] and 20 age-, sex- and race-matched controls. Height-Z was sig-
nificantly lower in HR-NBL survivors compared with controls (1.73 ± 1.38 vs. 0.34 ± 1.12, P < 0.001). Areal BMD-Z,
BMAD-Z, FMI-Z, visceral adipose tissue and subcutaneous adipose tissue were not significantly different in HR-NBL sur-
vivors compared with controls. Compared with controls, HR-NBL survivors had lower leg lean mass-Z (1.46 ± 1.35 vs.
 0.17 ± 0.84, P< 0.001) and strength-Z (1.13 ± 0.86 vs.  0.15 ± 0.71, P < 0.001). Muscle-specific force was lower
in HR-NBL survivors compared with controls (P < 0.05).
Conclusions Bone mineral density and adiposity are not severely impacted in HR-NBL survivors with growth failure,
but significant sarcopenia persists years after treatment. Future studies are needed to determine if sarcopenia improves
with muscle-specific interventions in this population of cancer survivors.
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Introduction
Therapeutic advances have transformed the prognosis for
high-risk neuroblastoma (HR-NBL) into a curable disease,
and the current 5-year event-free survival now approaches
50%.1 These survival improvements arise from intensive mul-
timodal approaches including high-dose chemotherapy, sur-
gery, tandem autologous stem cell transplant (ASCT),
radiation therapy, immunotherapy and biologic agents such
as cis-retinoic acid (cis-RA).2
Long-term survivors of HR-NBL exhibit a severe burden of
late effects.3 The combination of young age at diagnosis
and aggressive multimodal treatment, even in the absence
of total body irradiation (TBI), leads to marked growth failure
and short stature.4 We recently reported differences in
physeal structure between HR-NBL survivors and healthy
controls, suggesting poor growth plate architecture as the un-
derlying cause for abnormal growth.5 However, body compo-
sition abnormalities have not been well characterized in
HR-NBL survivors. Metabolic syndrome at rates higher than
healthy controls has been identified in survivors of neuroblas-
toma, but not specifically HR-NBL, who received abdominal
radiation.6 To date, few studies have examined bone mineral
deficits and body composition aberrations in survivors after
HR-NBL therapy, including immunotherapy and the biologic
agent cis-RA.7
cis-RA is a vitamin A derivative with multiple effects, in-
cluding osteoporosis and premature physeal plate closure.8,9
Guinea pigs treated with high doses of vitamin A demon-
strate physeal closure in the tibia and femur mediated by
retinoic acid receptors, as well as weight loss and poor
growth.10 Histological examination of cells treated with
retinoic acid reveals decreased physeal plate thickness and
disintegration of the growth plate.11,12 A case series identi-
fied three patients who developed premature physeal growth
arrest after isotretinoin exposure, with greater incidence of
bony abnormalities in patients diagnosed between ages 5
and 10 than in those diagnosed before the age of 5 and those
diagnosed after the age of 10.13 These studies suggest that
treatment of HR-NBL with cis-RA contributes to bony abnor-
malities in younger age, which is associated with substantial
skeletal morbidity in adulthood, including limb shortening,
deformity, fractures and osteonecrosis.14
Survivors of HR-NBL have numerous risk factors for abnor-
mal body composition, such as nutritional deficiencies and
endocrine abnormalities as a consequence of chemotherapy,
ASCT and radiation.6 Sarcopenia is the progressive loss of
muscle mass and function caused by ageing, disease and inac-
tivity; it is associated with physical disability and premature
mortality in survivors of ASCT.15–17 Sarcopenia has been dem-
onstrated in other populations of cancer survivors.17,18 Most
studies describing body composition abnormalities in survi-
vors of childhood cancer include a small number of patients
and an insufficiently robust control population necessary to
characterize body composition relative to age, sex, race, mat-
uration and body size. As a result, abnormalities in body com-
position in long-term survivors of HR-NBL have not been well
characterized.
The objective of this study was to assess areal bone min-
eral density (aBMD) and body composition using dual-energy
X-ray absorptiometry (DXA) in HR-NBL survivors treated with
cis-RA as part of neuroblastoma therapy. DXA is a method of
comprehensive bone and body composition assessment in
children.19 We have previously used DXA to demonstrate
body composition abnormalities in long-term survivors of
paediatric haematopoietic stem cell transplantation and
acute lymphoblastic leukaemia (ALL).20 We apply these tech-
niques to a population of long-term survivors of HR-NBL to
examine aBMD, lean mass, fat mass, visceral adiposity and
subcutaneous adiposity. Further, we examine
muscle-specific strength for functional assessment. We hy-
pothesized that HR-NBL survivors would have muscle deficits
compared with age-, sex- and race-matched controls. Our pri-
mary outcome was muscle mass and strength. Secondary
outcome was aBMD in order to better understand the func-
tional muscle-bone unit and the impact of muscle on bone.
Methods
Study sample
This was a prospective study of 20 survivors with history of
HR-NBL diagnosed and treated at the Children’s Hospital of
Philadelphia (CHOP) and 20 healthy age-, sex- and race-
matched controls. All survivors were recruited from CHOP on-
cology and endocrinology clinics. Inclusion criteria included
(1) diagnosis with HR-NBL per ANBL00B1 enrolment, (2)
treatment with cis-RA as part of HR-NBL therapy, (3) age 6–
16 years at time of enrolment and (4) in complete remission
for at least 2 years from completion of therapy. Exclusion
criteria included (1) treatment with bisphosphonates, (2) es-
timated glomerular filtration rate < 60 mL/min/1.73 m2,21
(3) full skeletal maturity determined by response to pubertal
development questionnaire and/or fusion of growth plates
on bone age evaluation, (4) active malignancy, (5) pregnancy
or (6) greater than 1-year post-menarche. Study participants
and their parent(s) were asked to categorize the participant’s
race according to the National Institute of Health categories.
Sex-, race- and age- (within 1 year) matched controls were re-
cruited from practices in the community consistent with our
prior studies and excluded based on (1) history of cancer;
(2) hepatic, renal, thyroid, neuromuscular or joint disease;
(3) skeletal maturity; (4) malabsorption syndromes; (5) med-
ications impacting growth or BMD; ( 6) use of oral retinoids
for acne; or (7) pregnancy.22
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The study was approved by the CHOP Institutional Review
Board, complied with Health Insurance Portability and Ac-
countability Act (HIPAA) guidelines, and was performed in ac-
cordance with the Declaration of Helsinki. Informed parental
consent and assent were obtained for all study participants.
Anthropometry and physical maturity
Height was measured with a stadiometer (Holtain, Crymych,
UK), and weight with a digital scale (Scale Tronix, White
Plains, NY). Sitting height was measured with a stadiometer
(Holtain, Crymych, UK) using a standardized stool. Sitting
height was defined as the difference between the height of
the participant seated on the stool and the height of the
stool. Sitting height index was defined as the ratio of sitting
height to standing height. Leg length was defined as the dif-
ference between standing height and sitting height. Tanner
pubertal stage was determined by a paediatric endocrinolo-
gist (SMM) in HR-NBL participants and by validated
self-assessment questionnaire in the control participants.23
For calculation of dorsiflexion Z-scores, tibia length was mea-
sured from the distal margin of the medial malleolus to the
proximal border of the medial tibial condyle.
HR-NBL disease and treatment characteristics
Participants were treated as per the Children’s Oncology
Group High Risk Neuroblastoma Consortium protocols CCG-
3891, CHP-594, ANBL0532, ANBL0931, ANBL09P1, ANBL0032
and/or ANBL1221. Medical charts were reviewed for date of
diagnosis, neuroblastoma primary site, metastatic burden,
detailed HR-NBL treatment regimen including cumulative
dose of cis-RA, number of ASCT, treatment response, pres-
ence or absence of relapse, additional relapse treatment reg-
imens and time since therapy completion. Other history
recorded included diagnosed and treated endocrine late ef-
fects such as thyroid hormone, growth hormone and gonadal
hormone replacements and all current medications.
As previously described,5 survivors with growth hormone
deficiency were diagnosed using conventional assessments,
which included growth failure, abnormal growth velocity for
age, laboratory testing and formal stimulation testing of the
growth axis.
The cumulative dose of cis-RA for each participant was cal-
culated as the sum of total milligram dose (mg/m2 body sur-
face area, multiplied by the participant’s body surface area)
for all cycles of therapy, as previously described.5
DXA
DXA scans were acquired using a Hologic Discovery bone den-
sitometer (Hologic, Bedford, MA). Whole-body and
non-dominant forearm scans were acquired in the array
mode. Posterior anterior lumbar spine (L1–L4) and left hip
scans were acquired in the fast array mode. Scans were
analysed using software versions 12.3 and 12.4 to generate ar-
eal BMD (g/cm3) and BMC (g). Spine phantoms were scanned
daily, and total body phantoms were scanned weekly. The pre-
cision error for aBMD and BMC was <1% for the spine and
<2.5% for the total body phantoms, respectively.
DXA measures of leg lean mass, appendicular lean mass
and total body lean mass (kg) (excluding bone mass) were ob-
tained from the total body scan as an index of skeletal muscle
in order to assess the relationship between muscle and bone,
as previously described.20 We have demonstrated that total
body lean mass underestimated muscle deficits in childhood
cancer survivors due to altered body proportions (longer legs
relative to height) following spine radiation.24
DXA whole-body fat mass (FM, kg) (excluding head) was
obtained as a measure of overall body adiposity. To interpret
fat mass relative to height, fat mass index (FMI) was calcu-
lated [FM/(height)2]. DXA abdominal visceral adipose tissue
(VAT) and subcutaneous adipose tissue (SAT) area (cm2) were
quantified in a 5-cm region at the L4 level (Hologic APEX 3.1
software) with VAT coefficient of variation reported at
2.3%.25
Three HR-NBL survivors were excluded from analysis of hip
scans (total hip and femoral neck), and one HR-NBL survivor
was excluded from analysis of lumbar spine due to the pres-
ence of indwelling hardware (secondary to treatment for sco-
liosis and/or slipped capital femoral epiphysis). These four
HR-NBL survivors were also excluded from analysis of TBLH
aBMD.
Measurement of muscle torque
Muscle torque was assessed by isometric ankle dynamometry
using the Biodex Multi-Joint System 3 Pro dynamometer
(Biodex Medical Systems, Inc., Shirley, NY). Muscle torque is
the gold standard for measuring muscle contractile force.26
For this system, high intra-rater (0.97–0.99) and inter-rater
(0.93–0.96) intraclass correlation coefficients have been
reported.27 Peak isometric torque (ft-lbs) was measured in
triplicate at 20° plantarflexion, and the highest value was re-
corded for dorsiflexion of the ankle. The test–retest repro-
ducibility in our laboratory for this measure (coefficient of
variation) is 4.3%.26
Physical activity
Physical activity was assessed in the HR-NBL survivors and
matched control participants using a questionnaire that cap-
tured over 30 sports and play activities, summarized as h/
week.28
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Fracture data
HR-NBL and control participant fracture summary was cap-
tured based on retrospective self-reported data. Low-impact
fractures were defined as fractures occurring after falls from
standing height or lower, without major trauma.
Laboratory studies
Laboratory studies were performed in HR-NBL survivors
only. IGF-1 levels (mg/dL) were measured by ELISA (R&D
Systems, Minneapolis, MN), and Z-scores were calculated
based on the manufacturer’s normal ranges for age and
Tanner stage.
Statistical analysis
Stata 16.0 (Stata Corp., College Station, TX) was used for all
statistical analyses. Age- and sex-specific Z-scores for height,
weight and body mass index were calculated using National
Center for Health Statistics data.29 Sitting height and leg
length Z-scores were calculated using reference ranges from
the National Health and Nutrition Examination Survey
(NHANES).30,31 Bone and body composition measures are
highly correlated with height. Therefore, adjustment for short
stature was performed for interpretation of bone and body
composition measures.32,33 Age-, sex- and race-specific Z-
scores were calculated for DXA aBMD, BMC and leg lean mass
using national reference data from the Bone Mineral Density
in Childhood Study (BMDCS).34 Height-for-age-Z-specific Z-
scores were calculated for aBMD and BMC; leg length-for-
age-specific Z-scores were calculated for leg lean mass.32
Age-, sex- and race-specific lumbar spine bone mineral appar-
ent density (BMAD) Z-scores (BMAD-Z) were developed using
BMDCS reference data.35 Sex-specific FMI Z-scores (FMI-Z),
appendicular lean mass index Z-scores and total body lean
mass index Z-scores were developed using NHANES reference
data.36
Dorsiflexion peak torque Z-scores (strength-Z) were cal-
culated based on age, sex, race and tibia length.37 We ex-
amined muscle torque relative to muscle size as a
measure of muscle quality26,38 by evaluating the differences
in strength-Z relative to HR-NBL survivorship status (HR-NBL
survivors compared with controls) with a linear regression,
adjusted for leg lean mass-Z. Reference data were not
available for VAT and SAT area. Therefore, differences in
VAT and SAT area relative to HR-NBL survivorship status
(HR-NBL survivors compared with controls) were evaluated
using linear regression, adjusted for the covariates age,
sex, FMI-Z and sitting height-Z. Pearson’s correlation was
used to calculate correlation coefficients for DXA BMD, fat
mass and lean mass outcomes and IGF-1-Z or 25(OH)D
level.
Categorical data were compared between HR-NBL survi-
vors and controls using Pearson’s chi-square test or Fisher’s
exact test. Distributions of all continuous variables were
examined for normality. Depending upon data normality,
group differences in continuous variables were assessed
using Student’s t-test or Mann–Whitney U test. Per cent of
subjects with low Z-scores in each group was inspected. A
P-value of <0.05 was considered statistically significant, and
two-sided tests of hypotheses were used throughout.
Results
Participant disease and treatment characteristics
Forty participants (20 survivors of HR-NBL and 20 healthy
matched controls; 13 males and 7 females per group) were
recruited during a 17-month period. We prospectively en-
rolled 20 (44%) of the total 45 eligible patients contacted.
Participant characteristics did not differ between enrolled
and eligible patients who declined study participation. The
group characteristics are summarized in Table 1, as previously
described by our group.5 HR-NBL survivors and control partic-
ipants were matched for age (HR-NBL participant mean age:
12.45 years, range: 9.46–16.03; control participant mean
age: 12.18 years, range: 10.36–14.11). The oldest survivor
had a younger control for comparison as we were unable to
identify an age-matched control with open growth plates.
None of the participants in the study had history of skeletal
trauma. HR-NBL survivors and control participants did not dif-
fer in the number of low-impact fractures or total fractures
(Table 1).
There were no significant differences in demographic
characteristics of the HR-NBL and control participants
(Table 1). HR-NBL was associated with delayed pubertal
maturation. As shown in Table 1, mean height Z-score for
HR-NBL survivors was lower compared with that of controls
(1.73 ± 1.38 vs. 0.34 ± 1.12, P < 0.001). Mean sitting
height Z-score was lower for HR-NBL survivors compared
with that of controls (1.38 ± 1.26 vs. 0.42 ± 1.04,
P < 0.001). However, sitting height index Z-score did not
differ between HR-NBL survivors and controls. The mean
leg length Z-score was lower for HR-NBL survivors com-
pared with that of controls (1.77 ± 1.31 vs. 0.10 ± 1.23,
P < 0.001).
Table 2 summarizes HR-NBL disease and treatment charac-
teristics. Seventeen HR-NBL survivors (85%) were diagnosed
with an endocrinopathy and treated with hormone replace-
ment therapy. Twelve survivors (60%) received growth hor-
mone for deficiency.
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Fifteen HR-NBL survivors received six cycles of cis-RA (Ta-
ble 2). Three survivors received slightly different courses
(5.5, 7 and 9 cycles), and two received extended cis-RA treat-
ment (14 and 17 cycles), due to relapse and refractory
disease. Eight HR-NBL survivors (40%) received TBI as part
of ASCT conditioning treatment regimen (Table 2).
aBMD measurements
Height-for-age-Z-adjusted aBMD Z-scores at all six sites exam-
ined (total body less head, lumbar spine, total hip, femoral
neck, distal 1/3 radius and ultradistal radius) did not differ be-
tween HR-NBL participants and controls (Table 1and Figure
1). One HR-NBL participant had low for age (Z-score ≤ 2.0)
HAZ-adjusted aBMD-Z at all six sites tested; this participant
did not receive TBI, was not growth hormone deficient and
had delayed pubertal development with no history of hor-
mone replacement therapy. HAZ-adjusted aBMD Z-scores less
than1.0 at the femoral neck were more common in HR-NBL
participants compared with controls (n = 9 vs. n = 4). Lumbar
spine BMAD-Z did not differ between HR-NBL participants
and controls (Table 1).
Table 1 Characteristics in high-risk neuroblastoma (HR-NBL) and matched-control participants
HR-NBL (n = 20) Matched controlsa (n = 20) P-value
Age at study enrolment, years 12.4 ± 1.6 12.2 ± 1.1 --
Sex, male, n (%) 13 (65%) 13 (65%) --
Race, black, n (%) 4 (20%) 4 (20%) --
Pubertal status, n (%)
Tanner Stage 1 10 (50%) 6 (30%) 0.07
Tanner Stages 2–3 9 (45%) 8 (40%)
Tanner Stages 4–5 1 (5%) 6 (30%)
Weight (kg) 35.8 ± 9.9 46.5 ± 12.6, 44.0d (32.3–86.4) <0.005
Weight Z-score 1.30 ± 1.43 0.34 ± 0.96 <0.001
Sitting height (cm) 73.0 ± 6.1 79.7 ± 5.4 <0.001
Sitting height Z-score 1.38 ± 1.26 0.42 ± 1.04 <0.001
Sitting height index Z-scoreb 0.68 ± 1.22 0.43 ± 0.86 0.45
Height (cm) 139.7 ± 12.0 153.5 ± 10.1 <0.001
Height Z-score 1.73 ± 1.38 0.34 ± 1.12 <0.001
BMI (kg/m2) 18.0 ± 2.4 19.5 ± 3.6, 18.8d (16.3–30.8) 0.13
BMI Z-score 0.25 ± 0.93 0.30 ± 0.90 0.09
Tibia length (cm) 32.3 ± 0.8 35.7 ± 0.6 <0.005
Leg length for age Z-score 1.77 ± 1.31 0.10 ± 1.23 <0.001
Physical activity levelc 2.6 ± 0.7 2.4 ± 0.6 0.47
Fracture history (any) 6 (30%) 8 (40%) 0.52
Low-impact fracture history 1 (5%) 1 (5%) --
TBLH aBMD height-adjusted Z-score 0.61 ± 1.17 0.58 ± 0.91 0.95
Lumbar spine aBMD height-adjusted Z-score 0.57 ± 1.30 0.08 ± 0.90 0.08
Lumbar spine BMAD Z-score 0.36 ± 1.49, 0.70d (3.47–2.06) 0.05 ± 0.97 0.12
Total hip aBMD height-adjusted Z-score 0.04 ± 1.18 0.07 ± 0.96 0.74
Femoral neck aBMD height-adjusted Z-score 0.77 ± 1.11 0.25 ± 0.90 0.13
Distal 1/3 radius aBMD height-adjusted Z-score 0.02 ± 1.07 0.22 ± 0.87, 0.05d (0.73–2.81) 0.96
Ultradistal radius aBMD height-adjusted Z-score 0.28 ± 1.71 0.18 ± 1.07 0.32
Total body lean mass index Z-score 1.21 ± 1.10 0.30 ± 0.83 <0.01
Appendicular lean mass index Z-score 1.38 ± 1.27 0.49 ± 0.91 <0.05
Leg lean mass adjusted for leg length Z-score 1.46 ± 1.35 0.17 ± 0.84 <0.001
Dorsiflexion peak torque Z-score 1.13 ± 0.86 0.15 ± 0.71 <0.001
Values are n (%) or mean ± standard deviation.
BMI, body mass index; TBLH, total body less head; BMAD, bone mineral apparent density.
aControls were sex, race and age matched (±1 year) to high-risk neuroblastoma participants.
bSitting height index was defined as the ratio of sitting height to standing height.
cPhysical activity level was quantified using the Physical Activity Questionnaire for Older Children (PAQ-C) or Adolescents (PAQ-A), where
applicable.28
dData were skewed so values are also reported as median (range).
Table 2 Disease and treatment characteristics in high-risk
neuroblastoma participants
Characteristics
Age at study enrolment, years 12.2 (9.5–15.8)
Age at diagnosis, years 2.8 (0.3–9.1)
Time since diagnosis, years 9.0 (3.0–15.5)
Total body irradiation 7 (35%)
cis-Retinoic acid 20 (100%)
Cumulative dose (mg) 8450 (5040–27,580)
IGF-1 Z-scorea 1.15 (2.10–5.70)
Endocrine abnormalities
Hypothyroidism on treatment 10 (50%)
Growth hormone deficient 15 (75%)
On growth hormone therapy at visit 12 (60%)
Response to growth hormone therapy 6 (50%)
Values are n (%) or median (range).
aIGF-1 level adjusted for age and Tanner stage.
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IGF-1 levels
IGF-1 Z-scores were low for age and pubertal status in four
HR-NBL survivors. Of those with low IGF-1 Z-scores, one male
was growth hormone deficient and had been previously
treated with growth hormone, one male was growth hor-
mone deficient with no history of growth hormone treat-
ment, and one female was growth hormone deficient with
no history of growth hormone treatment. One female did
not have prior diagnosis of growth hormone deficiency and
had not been treated with growth hormone. Greater total
body less head aBMD-Z (R = 0.72, P < 0.001), lumbar spine
aBMD-Z (R = 0.59, P = 0.01), total hip aBMD-Z (R = 0.54,
P = 0.047), ultradistal radius aBMD-Z (R = 0.59, P = 0.01)
and leg lean mass-Z (R = 0.53, P = 0.03) were associated with
greater IGF-1-Z.
Adiposity
HR-NBL participants had FMI-Z comparable with matched
controls (0.18 ± 0.64 vs.  0.11 ± 0.89, P = 0.76). DXA
VAT and SAT areas (cm2) were also comparable between
HR-NBL participants and controls [VAT area median (range):
33.8 (16.7–86.3) vs. 35.0 (11.2–95.8), P = 0.89; SAT area
99.6 (26.3–278.3) vs. 124.5 (28.4–537.7), P = 0.79]. The lack
of difference in VAT and SAT areas between HR-NBL partici-
pants and matched controls persisted in a linear regression
analysis with covariates age, sex, FMI-Z and sitting height-Z.
Lean body mass
Leg length-adjusted leg lean mass Z-score was significantly
lower in HR-NBL participants compared with controls
(1.46 ± 1.35 vs.  0.17 ± 0.84, P < 0.001) (Table 1 and
Figure 2). Leg lean mass Z-scores less than 2.0 were more
common in HR-NBL participants compared with controls
(n = 4 vs. n = 1). Similarly, leg lean mass Z-scores less than
1.0 were more common in HR-NBL participants compared
with controls (n = 11 vs. n = 1). Leg lean mass Z-scores were
highly correlated with total body lean mass index Z-scores
and appendicular lean mass index Z-scores (R = 0.9130,
P < 0.001 and R = 0.9323, P < 0.001, respectively).
Muscle strength and quality measurements
Strength-Z was lower in HR-NBL participants compared
with controls (1.13 ± 0.86 vs.  0.15 ± 0.71, P < 0.001)
(Table 1). Furthermore, assessment of muscle-specific
force through multivariate regression models demonstrated
that the negative association between HR-NBL status
and strength-Z remained significant when adjusted for leg
length-adjusted lean mass Z-score (Table 3).
Discussion
This is the first study to examine bone density, body compo-
sition and muscle strength outcomes in long-term survivors
of HR-NBL. In this contemporary cohort of survivors of
HR-NBL treated with cis-RA, we did not find bone density def-
icits after accounting for their short stature. However, we
found significant deficits in lean mass with low muscle-spe-
cific strength relative to age-, sex- and race-matched healthy
controls. The persistent low muscle mass and strength
(sarcopenia) are present in these survivors, years after com-
pletion of HR-NBL therapy.
There is a paucity of studies assessing sarcopenia in HR-
NBL. Kawakubo et al.39 performed a limited retrospective
study to assess the relationship between low muscle mass
and HR-NBL outcome. Based on CT-derived psoas muscle
area in 13 HR-NBL patients, those who maintained muscle
quantity over the course of HR-NBL treatment had longer
progression-free survival than patients who lost muscle mass
over their treatment course. Patients who relapsed or died
had lower psoas muscle area compared with patients with
Figure 1 Height-for-age-Z-adjusted areal BMD (aBMD) Z-scores for high-risk neuroblastoma (HR-NBL) and matched-control participants.
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progression-free survival. These results highlight the impor-
tance of low muscle mass as a potential marker of poor prog-
nosis in patients diagnosed with HR-NBL. However, this study
by Kawakubo et al. was limited by absence of functional mus-
cle assessment in HR-NBL patients. In our study, we per-
formed functional assessment using dynamometry,
demonstrating low muscle mass and low muscle-specific
strength in HR-NBL survivors, meeting the definition of
sarcopenia.15,16 Muscle was qualitatively different in
HR-NBL survivors compared with controls, given that differ-
ences were present even after adjustment for lower leg lean
mass.
There are several potential causes for sarcopenia in
HR-NBL survivors. The effects of intensive treatment, includ-
ing ASCT, cause disruption to the bone marrow milieu and
functional muscle–bone unit. Therapy for HR-NBL remains a
highly intense, multi-agent treatment regimen, and no singu-
lar treatment primarily contributes to the sarcopenia in
HR-NBL survivors. Recipients of bone marrow transplant
who receive similar chemotherapy and radiation regimens
demonstrate comparable lasting deficits.17,24 In addition,
low physical activity and nutritional deficiency as an effect
of treatment may also contribute to sarcopenia. Our findings
are in line with the presence of sarcopenia in other recipients
of ASCT such as Hodgkin or non-Hodgkin lymphoma.17 The
identification of sarcopenic obesity in these survivors was
also associated with increased mortality risk at 1 year and
at 5 years after ASCT compared with patients with normal
body composition.17 In a cohort of 19 HR-NBL survivors,
Vatanen et al.40 identified increased frailty (defined as having
three or more of the following: low muscle mass, low energy
expenditure, slow running and weakness) among HR-NBL par-
ticipants compared with age- and sex-matched controls. This
study also identified significantly shorter telomere length and
higher serum levels of high sensitivity C-reactive protein in
HR-NBL participants compared with controls, suggestive of
premature ageing. Despite comparable levels of physical ac-
tivity years after treatment in our cohort of HR-NBL survivors
compared with controls, levels of physical activity may have
been significantly lower during and shortly after completion
of HR-NBL treatment. Taken together, the concerning findings
of sarcopenia and premature ageing in survivors of HR-NBL
suggest the need to intervene and treat muscle deficits as a
serious late effect of intense HR-NBL treatment.
Figure 2 Leg length-adjusted lean mass Z-scores for high-risk neuroblastoma (HR-NBL) and matched-control participants. Figures were created using
Stata 16.0 (Stata Corp., College Station, TX) and Adobe Photoshop (Adobe, San Jose, CA).
Table 3 Differences in dorsiflexion Z-score outcome relative to high-risk neuroblastoma (HR-NBL) survivor status, with and without adjustment for leg
lean mass Z-score
β (95% CI) P-value
HR-NBL relative to
control participant status
HR-NBL relative to control participant status,
adjusted for leg lean mass Z-score
Difference in dorsiflexion Z-score 0.98 (1.40 to 0.46) P < 0.001 0.60 (1.14 to 0.06) P = 0.03
CI, confidence interval.
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The findings of lean mass and muscle strength deficits are
in line with our previous work in long-term survivors of allo-
geneic haematopoietic cell transplant.24 These transplant re-
cipients exhibited sarcopenic obesity, with greater trunk VAT
area and whole-body fat mass compared with age-, sex- and
race-matched controls.24 In contrast, HR-NBL survivors dem-
onstrated sarcopenia with no significant differences in adi-
pose measures compared with controls, potentially due to
less adipocyte differentiation from multipotent mesenchymal
stem cells related to differences in cancer treatment regimen.
In recipients of ASCT, sarcopenia alone was associated with
an increased mortality risk at 1 year and at 5 years after ASCT
compared with patients with normal body composition,17
underlining the importance of identifying sarcopenia in
HR-NBL survivors who received ASCT.
We identified lower height Z-score, sitting height Z-score
and leg length Z-score in HR-NBL survivors compared with
matched controls with preserved sitting height index Z-score,
demonstrating growth failure with proportionately shorter
bones. These anthropometric results indicate a defect in
overall growth, potentially due to direct effects of cis-RA on
the growth plate and secondary effects of growth hormone
deficiency, gonadal hormone deficiency and nutritional defi-
cits. The high prevalence of endocrine dysfunction identified
in this study highlight the importance of routine endocrinol-
ogy follow-up and provocative hormone testing for these
high-risk survivors.
No differences in height-for-age-Z-adjusted aBMD or
BMAD Z-scores were identified between HR-NBL and control
participants. These results are consistent with results from
Utriainen et al., who found that aBMD adjusted for bone size
did not differ between HR-NBL survivors and age- and sex-
matched controls.41 Despite significant short stature even in
the absence of TBI, our results suggest relative preservation
of BMD. Further, the lack of increased fractures in this cohort
of HR-NBL survivors is reassuring for preserved bone health.
The correlation between greater IGF-1 Z-score in HR-NBL sur-
vivors and greater leg lean mass Z-score and aBMD Z-score at
the total body less head, lumbar spine, total hip and
ultradistal radius is likely driven by the underlying growth
hormone treatment received by HR-NBL survivors with
growth hormone deficiency, given that the growth hor-
mone–IGF-1 axis drives the development of muscle and bone.
In contrast to our findings of preserved BMD in survivors of
HR-NBL, we have previously shown that survivors of ALL have
low total hip and femoral neck aBMD Z-scores compared with
national reference data.20 Moreover, long-term survivors of
paediatric allogeneic haematopoietic cell transplant had
lower trabecular volumetric BMD compared with reference
data.18 Compared with these two populations, the preserva-
tion of BMD in long-term survivors of HR-NBL may be due
to protective effects of ASCT preserving the bone marrow
trophic environment.
The primary limitations of our study are the cross-sectional
design, modest sample size, lack of muscle biopsies and lack
of laboratory measurements in the matched controls. Ab-
sence of longitudinal evaluation prohibits assessment of
changes in DXA or dynamometry outcomes over time. The ex-
tended duration since completion of treatment prohibits ex-
amining the immediate impact of cis-RA, chemotherapy and
ASCT on bone and body composition. Finally, the study did
not use objective measures of physical activity, such as use
of accelerometers.
However, this study has many important strengths. We
present the first prospective study to evaluate lean mass in
HR-NBL survivors using DXA and muscle function using dyna-
mometry, demonstrating low muscle strength after adjusting
for low lean mass—consistent with both low muscle mass
and abnormal quality. We provide a thorough assessment
of bone outcomes at multiple DXA sites following multi-
modal therapy for HR-NBL. Although BMD deficits have
been identified in survivors of other paediatric malignancies,
this cohort of HR-NBL survivors exhibited appropriate bone
health for their degree of short stature. We also recruited
a comparison group of age-, sex- and race-matched healthy
controls.
In conclusion, the combination of markedly decreased leg
lean mass and decreased muscle-specific strength underline
the substantial burden of long-term sarcopenia, with the
need for earlier interventions to target muscle development
in HR-NBL patients. Rather than targeting interventions years
after completion of HR-NBL treatment, we anticipate that
muscle gains may be most impactful if muscle is targeted in
early treatment stages. Rigorous proactive exercise interven-
tions, such as those employed for ALL,42,43 may have a role in
the routine prophylactic treatment of HR-NBL. Future longi-
tudinal studies are essential to determine the mechanism of
sarcopenia and long-term complications secondary to
sarcopenia and to identify strategies that not only promote
normal muscle accrual but also improve muscle-specific
strength in the growing number of HR-NBL survivors.
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